Prognostication algorithm for non-cirrhotic non-B non-C hepatocellular carcinoma-a multicenter study under the aegis of the French Association of Hepato-Biliary Surgery and liver Transplantation  

作　　者：Charlotte Maulat Stéphanie Truant Christian Hobeika Louise Barbier Astrid Herrero Alexandre Doussot Johan Gagnière Édouard Girard Hadrien Tranchart Jean-Marc Regimbeau David Fuks François Cauchy Mathieu Prodeau Antoine Notte Cyprien Toubert Ephrem Salamé Mehdi El Amrani Sandrine Andrieu Fabrice Muscari Jason Shourick Bertrand Suc 

机构地区：[1]Department of Digestive Surgery,Hepatobiliary and Pancreatic Surgery and Liver Transplantation Unit,Toulouse University Hospital,Toulouse,France [2]Department of Digestive Surgery and Transplantation,Claude-Huriez,Hospital,CHRU Lille,Lille,France [3]CANTHER laboratory“Cancer Heterogeneity,Plasticity and Resistance to Therapies”,Inserm UMR-S1277 Teams“Mucins,Cancer and Drug Resistance”,Lille,France [4]Department of Hepato-bilio-pancreatic Surgery and Liver Transplantation,Beaujon Hospital,APHP,Clichy,France [5]Department of Digestive Surgery and Liver Transplantation,Trousseau Hospital,Tours University Hospital,Tours,France [6]Department of Digestive Surgery and Liver Transplantation,Saint Eloi Hospital,Montpellier University Hospital,Montpellier,France [7]Department of Digestive Surgery and Liver Transplantation,Besançon University Hospital,Besançon,France [8]Department of Digestive and Hepatobiliary Surgery,University Hospital of Clermont-Ferrand,Clermont-Ferrand,France [9]U1071 Inserm/UniversitéClermont-Auvergne,Clermont-Ferrand,France [10]Department of Digestive Surgery and Emergency,CHU Grenoble-Alpes,Grenoble,France [11]Department of Mini-invasive Surgery,Antoine Béclère Hospital,APHP,Clamart,France [12]Department of Digestive Surgery,Amiens Picardie University Hospital and Picardie Jules Verne University,Amiens,France [13]Department of Digestive Surgery,Institut Mutualiste Montsouris,Paris,France [14]Department of Epidemiology,Toulouse University Hospital,Toulouse,France

出　　处：《Hepatobiliary Surgery and Nutrition》2023年第2期192-204,I0002-I0004,共16页肝胆外科与营养（英文）

摘　　要：Background:Liver resection and local ablation are the only curative treatment for non-cirrhotic hepatocellular carcinoma(HCC).Few data exist concerning the prognosis of patients resected for non-cirrhotic HCC.The objectives of this study were to determine the prognostic factors of recurrence-free survival(RFS)and overall survival(OS)and to develop a prognostication algorithm for non-cirrhotic HCC.Methods:French multicenter retrospective study including HCC patients with non-cirrhotic liver without underlying viral hepatitis:F0,F1 or F2 fibrosis.Results:A total of 467 patients were included in 11 centers from 2010 to 2018.Non-cirrhotic liver had a fibrosis score of F0(n=237,50.7%),F1(n=127,27.2%)or F2(n=103,22.1%).OS and RFS at 5 years were 59.2%and 34.5%,respectively.In multivariate analysis,microvascular invasion and HCC differentiation were prognostic factors of OS and RFS and the number and size were prognostic factors of RFS(P<0.005).Stratification based on RFS provided an algorithm based on size(P=0.013)and number(P<0.001):2 HCC with the largest nodule≤10 cm(n=271,Group 1);2 HCC with a nodule>10 cm(n=176,Group 2);>2 HCC regardless of size Conclusions:We developed a prognostication algorithm based on the number(≤or>2)and size(≤or>10 cm),which could be used as a treatment decision support concerning the need for perioperative therapy.In case of bifocal HCC,surgery should not be a contraindication.

关 键 词：Hepatocellular carcinoma(HCC) non-cirrhotic liver prognostic factors recurrence-free survival(RFS) prognostication algorithm 

分 类 号：R735.7[医药卫生—肿瘤]